{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:31:07Z","timestamp":1773297067915,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00277-011-1199-y","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T19:17:28Z","timestamp":1299007048000},"page":"1307-1315","source":"Crossref","is-referenced-by-count":15,"title":["Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with 131I-anti-CD20 antibody and stem cell rescue"],"prefix":"10.1007","volume":"90","author":[{"given":"Karin","family":"Hohloch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten Oliver","family":"Sahlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijai J.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Gla\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Meller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Riggert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,1]]},"reference":[{"issue":"12","key":"1199_CR1","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12):3725\u20133732","journal-title":"Blood"},{"issue":"5","key":"1199_CR2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"issue":"10","key":"1199_CR3","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","volume":"4","author":"CJ Gallagher","year":"1986","unstructured":"Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS et al (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4(10):1470\u20131480","journal-title":"J Clin Oncol"},{"issue":"5 Suppl 5","key":"1199_CR4","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20(5 Suppl 5):75\u201388","journal-title":"Semin Oncol"},{"issue":"3","key":"1199_CR5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00277-009-0820-9","volume":"89","author":"A Borgerding","year":"2010","unstructured":"Borgerding A, Hasenkamp J, Glass B, Wulf G, Trumper L (2010) Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol 89(3):283\u2013289","journal-title":"Ann Hematol"},{"issue":"27","key":"1199_CR6","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh GD, Linch DC, Trneny M et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184\u20134190","journal-title":"J Clin Oncol"},{"issue":"23","key":"1199_CR7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der LH, Bron D et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333(23):1540\u20131545","journal-title":"N Engl J Med"},{"issue":"33","key":"1199_CR8","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP (2005) New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23(33):8447\u20138452","journal-title":"J Clin Oncol"},{"issue":"7","key":"1199_CR9","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105(7):2677\u20132684","journal-title":"Blood"},{"issue":"9","key":"1199_CR10","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","volume":"104","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104(9):2667\u20132674","journal-title":"Blood"},{"issue":"8","key":"1199_CR11","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","volume":"106","author":"A Nademanee","year":"2005","unstructured":"Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A et al (2005) A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106(8):2896\u20132902","journal-title":"Blood"},{"issue":"8971","key":"1199_CR12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","volume":"346","author":"OW Press","year":"1995","unstructured":"Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S et al (1995) Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346(8971):336\u2013340","journal-title":"Lancet"},{"issue":"3","key":"1199_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1200\/JCO.2005.05.117","volume":"23","author":"JM Vose","year":"2005","unstructured":"Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC et al (2005) Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23(3):461\u2013467","journal-title":"J Clin Oncol"},{"key":"1199_CR14","unstructured":"Griesinger F (2007) Myeloablative Hochdosis-RIT bei rezidivierten B-Zell-NHL mit 131-I-Rituximab: Erfahrungen der G\u00f6ttinger RIT-Gruppe. In: Truemper L (ed) Radioimmuntherapie in der H\u00e4matologie und Onkologie. Unimed Science, pp 110\u2013220"},{"issue":"4","key":"1199_CR15","first-page":"508","volume":"31","author":"KS Weadock","year":"1990","unstructured":"Weadock KS, Sharkey RM, Varga DC, Goldenberg DM (1990) Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 31(4):508\u2013511","journal-title":"J Nucl Med"},{"issue":"12","key":"1199_CR16","first-page":"2102","volume":"40","author":"S Shen","year":"1999","unstructured":"Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ (1999) Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 40(12):2102\u20132106","journal-title":"J Nucl Med"},{"issue":"3","key":"1199_CR17","first-page":"538","volume":"37","author":"MG Stabin","year":"1996","unstructured":"Stabin MG (1996) MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37(3):538\u2013546","journal-title":"J Nucl Med"},{"issue":"4","key":"1199_CR18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"issue":"12","key":"1199_CR19","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2004-12-4690","volume":"105","author":"JM Bennett","year":"2005","unstructured":"Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ et al (2005) Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105(12):4576\u20134582","journal-title":"Blood"},{"issue":"10","key":"1199_CR20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","volume":"27","author":"JN Winter","year":"2009","unstructured":"Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W et al (2009) Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 27(10):1653\u20131659","journal-title":"J Clin Oncol"},{"issue":"9","key":"1199_CR21","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","volume":"96","author":"OW Press","year":"2000","unstructured":"Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG et al (2000) A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96(9):2934\u20132942","journal-title":"Blood"},{"issue":"11","key":"1199_CR22","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","volume":"25","author":"AK Gopal","year":"2007","unstructured":"Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH et al (2007) High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 25(11):1396\u20131402","journal-title":"J Clin Oncol"},{"issue":"32","key":"1199_CR23","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","volume":"26","author":"L Devizzi","year":"2008","unstructured":"Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E et al (2008) High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 26(32):5175\u20135182","journal-title":"J Clin Oncol"},{"issue":"2","key":"1199_CR24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","volume":"111","author":"E Vellenga","year":"2008","unstructured":"Vellenga E, van Putten WL, van Van\u2019t Veer MB, Zijlstra JM, van Fibbe WE, van Oers MH (2008) Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 111(2):537\u2013543","journal-title":"Blood"},{"issue":"1\u20132","key":"1199_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/10428190009057634","volume":"37","author":"A Josting","year":"2000","unstructured":"Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Sohngen D et al (2000) Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue\u2013a highly effective regimen for patients with refractory or relapsed indolent lymphoma. Leuk Lymphoma 37(1\u20132):115\u2013123","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1199_CR26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MOH.0b013e3282efb17c","volume":"14","author":"SI Park","year":"2007","unstructured":"Park SI, Press OW (2007) Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 14(6):632\u2013638","journal-title":"Curr Opin Hematol"},{"issue":"Suppl 2","key":"1199_CR27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1634\/theoncologist.2009-S2-41","volume":"14","author":"C Gisselbrecht","year":"2009","unstructured":"Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A (2009) Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist 14(Suppl 2):41\u201351","journal-title":"Oncologist"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1199-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-011-1199-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-011-1199-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:01:56Z","timestamp":1592352116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-011-1199-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s00277-011-1199-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}